drugset
drugset / Trial / NCT03154047

Study in Subjects With Light Chain (AL) Amyloidosis

NCT03154047 ↗

Phase 2 Terminated 80 enrolled Prothena Biosciences Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.

Timeline

Start
2017-06-14
Primary completion
2018-05-30
Completion
2018-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Birtamimab Monoclonal antibody — —

Indications

AL amyloidosis